NAD+
REC PPT-NAD // REV 2026-10-04 // assessment changes are logged, never silent
A coenzyme, not a peptide. Precursors have better human data than NAD+ itself.
What it is
Nicotinamide adenine dinucleotide — a coenzyme central to cellular energy metabolism. Not a peptide, though sold alongside them.
What it does
Levels decline with age; supplementation aims to restore cellular NAD+ availability.
Does it work?
Human trials mostly study oral precursors (NR, NMN) rather than injected NAD+, and results on ageing outcomes are mixed. Direct infusion is popular in clinics but less well studied than the marketing implies.
Claims vs data
Each marketing claim, tagged by what the evidence actually supports.
| Oral precursors raise NAD+ levels | supported |
| Slows human ageing | weak evidence |
| IV NAD+ is better studied than oral precursors | overreach |
Reference figures
Quoted from published reference material. These are not Peptuity recommendations.
molecular data — PubChem CID 5892
The evidence, counted
Live counts from Europe PMC and ClinicalTrials.gov.
14 publications indexed, but only 2 randomised controlled trials and 102 registered interventional studies. Human evidence exists but is thin.
SRC // EUROPE PMC + CTGOV // "nicotinamide adenine dinucleotide supplementation" // FETCHED 2026-10-04 // 14 RECORDS
Most-cited literature
-
[01]
Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial
Chung CL, Lawrence I, Hoffman M, Elgindi D, Nadhan K, Potnis M, Jin A, · Geroscience 2019 · 170 citations · DOI 10.1007/s11357-019-00113-y
-
[02]
A systematic review of mitochondrial abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome/systemic exertion intolerance disease
Holden S, Maksoud R, Eaton-Fitch N, Cabanas H, Staines D, Marshall-Gra · J Transl Med 2020 · 60 citations · DOI 10.1186/s12967-020-02452-3
-
[03]
Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome - A randomized, con
Castro-Marrero J, Sáez-Francàs N, Segundo MJ, Calvo N, Faro M, Aliste · Clin Nutr 2016 · 51 citations · DOI 10.1016/j.clnu.2015.07.010
-
[04]
Clinical Evidence for Targeting NAD Therapeutically
Radenkovic D, Reason, Verdin E. · Pharmaceuticals (Basel) 2020 · 49 citations · DOI 10.3390/ph13090247
Common questions
Is NAD+ a peptide?
No — it is a coenzyme central to energy metabolism. It is sold alongside peptides but is a different class of molecule.
Are the IV drips better than oral precursors?
The human trial literature mostly studies oral precursors like NR and NMN. Direct NAD+ infusion is popular in clinics but less studied than the marketing implies.
Does raising NAD+ slow ageing?
Levels decline with age and restoring them is a plausible hypothesis — but human outcome data on ageing endpoints is mixed and incomplete.
Related compounds
MOTS-c
Mitochondrial-derived peptide. Interesting biology, minimal human data.
SS-31
Mitochondria-targeted peptide with genuine clinical development history.
5-Amino-1MQ
Small-molecule NNMT inhibitor, not a peptide. Preclinical only.
Epitalon
Soviet-era longevity peptide. Claims far exceed independently replicated evidence.